Healing & Recovery

Thymosin Alpha-1 is a 28-amino acid immunomodulatory peptide naturally occurring in the thymus gland that has been extensively studied for its ability to enhance and restore immune function. The peptide acts through Toll-like receptors in dendritic cells, promoting T-cell differentiation and maturation, activating natural killer cells, and modulating cytokine production. With over 4,400 subjects enrolled in clinical trials across the United States, Europe, and China, Thymosin Alpha-1 has demonstrated efficacy in treating chronic hepatitis B and C, cancer immunotherapy, sepsis, COVID-19, and as a vaccine adjuvant. The synthetic form, thymalfasin (Zadaxin), has received regulatory approval in over 30 countries for conditions including hepatitis B, hepatocellular carcinoma, and malignant melanoma. However, it is not FDA-approved in the United States, though it received orphan drug designation. Clinical experience involving over 11,000 subjects across more than 30 trials demonstrates a favorable safety profile with only minor, transient side effects, primarily mild injection site reactions. The peptide is typically administered subcutaneously at doses of 0.8-6.4 mg twice weekly.

LL-37 is the sole human member of the cathelicidin family of antimicrobial peptides, derived from the C-terminal fragment of the human cationic antimicrobial protein 18 (hCAP18). This 37-amino acid peptide was identified in the 1990s as a critical component of human innate immunity. LL-37 functions through multiple mechanisms including direct antimicrobial activity via membrane disruption, immunomodulation through regulation of inflammatory responses, chemotaxis of immune cells, lipopolysaccharide neutralization, and promotion of wound healing and angiogenesis. The peptide is expressed in epithelial tissues of the skin, gastrointestinal tract, respiratory tract, and in various leukocytes including neutrophils, monocytes, and lymphocytes. Its expression is regulated by vitamin D, bacterial components, cytokines, and tissue injury signals. Currently, LL-37 is not FDA-approved for therapeutic use and remains available only for research purposes, though phase 1 clinical trials have been completed for melanoma and exploratory studies conducted for COVID-19 and sepsis.

MGF (Mechano Growth Factor) is a splice variant of Insulin-like Growth Factor 1 (IGF-1) that plays a crucial role in muscle repair, tissue regeneration, and neuroprotection. It is produced in response to mechanical stress and muscle damage, activating satellite cells and promoting tissue healing. MGF is also known as IGF-1Ec in humans and IGF-1Eb in rodents, characterized by a unique E domain resulting from alternative splicing of the IGF-1 gene.

Vesugen (KED) is a synthetic tripeptide bioregulator consisting of lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp), developed by Dr. Vladimir Khavinson for vascular health. Research demonstrates its ability to increase microvascular density in aged animals by 2.5-2.8 times and normalize endothelial cell function through epigenetic regulation of gene expression. Clinical studies in elderly patients show effectiveness in treating atherosclerosis, improving microcirculation, and protecting blood vessels from age-related dysfunction. The peptide acts as a geroprotector with vasoprotective properties, regulating expression of key proteins including Ki-67, SIRT1, endothelin-1, and connexin-37.

Vilon is a synthetic dipeptide bioregulator composed of lysine and glutamic acid (Lys-Glu) developed by Professor Vladimir Khavinson. It acts as an immunomodulatory agent that supports thymic function, stimulates T-cell differentiation and proliferation, and demonstrates anti-aging properties through chromatin reactivation in senescent cells. Research shows Vilon can inhibit tumor growth, extend lifespan in animal models, protect against radiation-induced aging, and modulate inflammatory pathways.

Cardiogen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Dr. Vladimir Khavinson in Russia during the 1980s-90s. It acts as a cardioprotective agent that regulates gene expression and protein synthesis in cardiac tissue, particularly targeting fibroblasts responsible for tissue repair. Studies demonstrate its ability to enhance cytoskeletal and nuclear matrix protein expression, reduce apoptosis through p53 modulation, and protect myocardial tissue following ischemic injury. While extensively studied in animal models, human clinical trials remain limited.

Thymalin is a polypeptide complex extracted from calf thymus tissue, developed by Prof. Vladimir Khavinson in the 1970s as an immunomodulatory bioregulator. It contains short peptides (KE, EW, EDP) that epigenetically regulate gene expression, stimulate hematopoietic stem cell differentiation into T-lymphocytes, and modulate inflammatory pathways. Extensive clinical research in Russia demonstrates geroprotective effects, with 2-4 fold mortality reduction in elderly populations and efficacy in treating immune dysfunction, viral infections, cancer support, and COVID-19.

TB-500 (Thymosin Beta-4) is a naturally occurring 43-amino acid peptide that functions as the major G-actin-sequestering molecule in mammalian cells. It plays crucial roles in tissue repair, wound healing, and cellular regeneration by regulating cell migration, proliferation, and differentiation. The peptide has demonstrated significant therapeutic potential in multiple clinical applications including dermal wound healing, corneal injuries, dry eye disease, and cardiac tissue repair following myocardial infarction. Phase I and Phase II clinical trials have established its safety profile at various dosing regimens, though it remains unapproved by regulatory agencies. TB-500 is sold on the gray market as a research chemical and is prohibited in competitive sports by the World Anti-Doping Agency due to its performance-enhancing and tissue regeneration properties.

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a naturally occurring copper-binding tripeptide first isolated from human plasma in 1973. It functions as a signaling molecule that modulates multiple cellular pathways involved in tissue repair and regeneration. The peptide's concentration in human plasma declines from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60, correlating with decreased regenerative capacity. GHK-Cu works through several mechanisms including copper ion transport, gene expression modulation (affecting over 4,000 human genes), collagen and elastin synthesis stimulation, antioxidant activity via superoxide dismutase enhancement, and growth factor pathway activation. Research demonstrates efficacy in wound healing, skin regeneration, hair follicle stimulation, and anti-inflammatory responses across multiple tissue types. The peptide is not FDA-approved for therapeutic use but is widely used in cosmetic products. It was recently added to FDA's Category 1 bulk substances list for 503A compounding, though not for injectable routes. GHK-Cu is available primarily through compounding pharmacies for research purposes and in topical cosmetic formulations marketed for anti-aging and skin rejuvenation applications.

Pentosan polysulfate sodium (PPS), marketed as Elmiron, is a semi-synthetic sulfated polysaccharide and the only FDA-approved oral medication for treating bladder pain and discomfort associated with interstitial cystitis/bladder pain syndrome (IC/BPS). FDA-approved in 1996, PPS works by adhering to the bladder wall to restore the defective glycosaminoglycan layer, acting as a protective barrier against irritating urinary substances. While clinical trials demonstrate efficacy in reducing pain, urgency, and urinary frequency, long-term use has been associated with a dose-dependent risk of pentosan polysulfate maculopathy (PPSM), a potentially vision-threatening retinal condition that has led to updated FDA labeling and screening recommendations.

PEG-MGF is a synthetically modified version of Mechano Growth Factor (MGF), a splice variant of Insulin-like Growth Factor-1 (IGF-1Ec). Through pegylation - the attachment of polyethylene glycol molecules - and the substitution of L-arginine with D-arginine, PEG-MGF achieves dramatically extended stability and half-life compared to native MGF. This peptide plays a crucial role in tissue repair and regeneration by activating satellite cells (muscle stem cells), promoting cellular proliferation, and providing anti-apoptotic effects. PEG-MGF is particularly responsive to mechanical stress and injury, making it a key factor in muscle repair, cardiac protection, bone healing, cartilage regeneration, and neuroprotection.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (sequence: GEPPPGKPADDAGLV) derived from a protective protein found in human gastric juice. The peptide demonstrates pleiotropic biological activity through multiple mechanisms, including stimulation of vascular endothelial growth factor (VEGF) expression and VEGFR2 receptor activation, enhancement of growth hormone receptor expression, activation of the FAK-paxillin pathway for cell migration, and modulation of the nitric oxide system via Src-Caveolin-1-eNOS signaling. Preclinical research in animal models has shown consistent healing effects across diverse tissue types including tendons, ligaments, muscles, bones, gastrointestinal mucosa, and neural tissue. While BPC-157 was tested in Phase I clinical trials for inflammatory bowel disease (PL14736) by Pliva, Croatia, human clinical data remains extremely limited with only one small retrospective study in musculoskeletal pain. The FDA classified BPC-157 as a Category 2 bulk drug substance in 2023, prohibiting compounding due to insufficient safety evidence in humans. The World Anti-Doping Agency (WADA) and major sports organizations ban its use. Despite lack of FDA approval, the peptide is available through gray market channels and increasingly used by clinicians and athletes, raising significant safety and regulatory concerns.

Bronchogen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu/AEDL) developed by Vladimir Khavinson for respiratory system support. This short peptide interacts directly with DNA and histone proteins to regulate gene expression in bronchial epithelium, promoting differentiation and functional activity of lung cells. Research demonstrates its ability to stabilize DNA, reduce inflammation, restore epithelial integrity, and enhance surfactant production in animal models of chronic obstructive pulmonary disease (COPD) and lung injury.

Glutathione (GSH) is a tripeptide composed of glutamate, cysteine, and glycine that serves as the body's most abundant endogenous antioxidant and critical regulator of oxidative stress, redox homeostasis, and immune function. It functions through direct neutralization of free radicals and as a cofactor for antioxidant enzymes like glutathione peroxidase. Research applications span neurodegenerative diseases (Alzheimer's, Parkinson's), metabolic disorders (diabetes, NAFLD), respiratory conditions (COPD), immune function (COVID-19), exercise performance, and dermatological applications. Clinical trials demonstrate that oral supplementation (250-1000 mg daily) can increase tissue glutathione levels by 17-35% in blood compartments and up to 260% in buccal cells, with evidence showing improvements in oxidative stress markers, glycemic control in diabetics, liver function in NAFLD, and reduced muscle fatigue. Glutathione is not FDA-approved as a drug but is available as a dietary supplement; intravenous formulations lack FDA approval for cosmetic uses and carry safety concerns. The compound is widely researched with generally favorable safety profiles for oral and topical administration.

Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme found in all living cells, first discovered by British biochemist Arthur Harden and colleagues in 1906 while studying fermentation. NAD+ functions as a critical electron carrier in cellular metabolism and serves as a substrate for enzymes including sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38. Its primary mechanisms involve facilitating redox reactions in energy metabolism, regulating mitochondrial function, supporting DNA repair processes, and modulating cellular signaling pathways. Research areas include aging and longevity, metabolic disorders, cardiovascular health, neurodegenerative diseases, and mitochondrial dysfunction. NAD+ levels naturally decline with age, prompting investigation of supplementation with precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). While NAD+ itself is not FDA-approved as a drug, precursors such as NR have received Generally Recognized as Safe (GRAS) status and are commercially available as dietary supplements.

KPV is a tripeptide consisting of lysine-proline-valine, derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (α-MSH). This short peptide exhibits potent anti-inflammatory properties without the pigmentation effects associated with full-length α-MSH. [1][2] The peptide functions by modulating inflammatory pathways, particularly through inhibition of pro-inflammatory cytokines and regulation of NF-κB signaling. Research has demonstrated its ability to reduce inflammation in various tissue types, with particular interest in gastrointestinal applications for inflammatory bowel disease. [3][4] KPV can be administered orally, topically, or via injection, with each route showing different tissue targeting properties. The oral route appears particularly promising for gut-targeted anti-inflammatory effects, while topical application may benefit skin conditions. Research remains largely preclinical, with human clinical trials still limited. [5][6]